|
1
|
Lizarbe MA, Barrasa JI, Olmo N, Gavilanes F and Turnay J: Annexin-phospholipid interactions. Functional implications. Int J Mol Sci. 14:2652–2683. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markoff A and Gerke V: Expression and functions of annexins in the kidney. Am J Physiol Renal Physiol. 289:F949–F956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu N, Liu S, Guo C, Hou Z and Sun MZ: The role of annexin A3 playing in cancers. Clin Transl Oncol. 15:106–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gerke V and Moss SE: Annexins: From structure to function. Physiol Rev. 82:331–371. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rescher U and Gerke V: Annexins - unique membrane binding proteins with diverse functions. J Cell Sci. 117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganesan T, Sinniah A, Ibrahim ZA, Chik Z and Alshawsh MA: Annexin A1: A bane or a boon in cancer? Molecules. 25:37002020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christensen MV, Høgdall CK, Jochumsen KM and Høgdall EVS: Annexin A2 and cancer: A systematic review. Int J Oncol. 52:5–18. 2018.PubMed/NCBI
|
|
8
|
Park JE, Lee DH, Lee JA, Park SG, Kim NS, Park BC and Cho S: Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun. 337:1283–1287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mohr T, Haudek-Prinz V, Slany A, Grillari J, Micksche M and Gerner C: Proteome profiling in IL-1β and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PLoS One. 12:e01790652017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niimi S, Harashima M, Gamou M, Hyuga M, Seki T, Ariga T, Kawanishi T and Hayakawa T: Expression of annexin A3 in primary cultured parenchymal rat hepatocytes and inhibition of DNA synthesis by suppression of annexin A3 expression using RNA interference. Biol Pharm Bull. 28:424–428. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harashima M, Harada K, Ito Y, Hyuga M, Seki T, Ariga T, Yamaguchi T and Niimi S: Annexin A3 expression increases in hepatocytes and is regulated by hepatocyte growth factor in rat liver regeneration. J Biochem. 143:537–545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mussunoor S and Murray GI: The role of annexins in tumour development and progression. J Pathol. 216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huber R, Berendes R, Burger A, Luecke H and Karshikov A: Annexin V-crystal structure and its implications on function. Behring Inst Mitt. 91:107–125. 1992.PubMed/NCBI
|
|
14
|
Réty S, Sopková-de Oliveira Santos J, Dreyfuss L, Blondeau K, Hofbauerová K, Raguénès-Nicol C, Kerboeuf D, Renouard M, Russo-Marie F and Lewit-Bentley A: The crystal structure of annexin A8 is similar to that of annexin A3. J Mol Biol. 345:1131–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hofmann A, Raguénès-Nicol C, Favier-Perron B, Mesonero J, Huber R, Russo-Marie F and Lewit-Bentley A: The annexin A3-membrane interaction is modulated by an N-terminal tryptophan. Biochemistry. 39:7712–7721. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perron B, Lewit-Bentley A, Geny B and Russo-Marie F: Can enzymatic activity, or otherwise, be inferred from structural studies of annexin III? J Biol Chem. 272:11321–11326. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sopkova J, Raguenes-Nicol C, Vincent M, Chevalier A, Lewit-Bentley A, Russo-Marie F and Gallay J: Ca(2+) and membrane binding to annexin 3 modulate the structure and dynamics of its N terminus and domain III. Protein Sci. 11:1613–1625. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Le Cabec V, Russo-Marie F and Maridonneau-Parini I: Differential expression of two forms of annexin 3 in human neutrophils and monocytes and along their differentiation. Biochem Biophys Res Commun. 189:1471–1476. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nishiura H, Yamanegi K, Kawabe M, Kato-Kogoe N, Yamada N and Nakasho K: Annexin A3 plays a role in cytoplasmic calcium oscillation by extracellular calcium in the human promyelocytic leukemia HL-60 cells differentiated by phorbol-12-myristate-13-acetate. Exp Mol Pathol. 97:241–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Junker H, Suofu Y, Venz S, Sascau M, Herndon JG, Kessler C, Walther R and Popa-Wagner A: Proteomic identification of an upregulated isoform of annexin A3 in the rat brain following reversible cerebral ischemia. Glia. 55:1630–1637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hamelin-Peyron C, Vlaeminck-Guillem V, Haïdous H, Schwall GP, Poznanović S, Gorius-Gallet E, Michel S, Larue A, Guillotte M, Ruffion A, et al: Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability. Clin Biochem. 47:901–908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zamora DO, Riviere M, Choi D, Pan Y, Planck SR, Rosenbaum JT, David LL and Smith JR: Proteomic profiling of human retinal and choroidal endothelial cells reveals molecular heterogeneity related to tissue of origin. Mol Vis. 13:2058–2065. 2007.PubMed/NCBI
|
|
23
|
Bianchi C, Bombelli S, Raimondo F, Torsello B, Angeloni V, Ferrero S, Di Stefano V, Chinello C, Cifola I, Invernizzi L, et al: Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Am J Pathol. 176:1660–1670. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu CM, Lin JJ, Huang HH, Ko YC, Hsu JL, Chen JC, Din ZH and Wu YJ: A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis. BMC Cancer. 14:3632014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB and Liu Y: Impact of Annexin A3 expression in gastric cancer cells. Neoplasma. 61:257–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai JM, Sun SJ, Wang W and Zeng C: Expression of annexin A3 in gastric cancer and its correlation with proliferation and apoptosis. Asian Pac J Cancer Prev. 15:3001–3004. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Endl E and Gerdes J: The Ki-67 protein: Fascinating forms and an unknown function. Exp Cell Res. 257:231–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cang S, Iragavarapu C, Savooji J, Song Y and Liu D: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 8:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang K and Li J: Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth. Oncotarget. 7:86972–86984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Jia X, Meng X, Li Y, Wu W, Zhang X, Xu H and Cui J: Annexin A3 may play an important role in ochratoxin-induced malignant transformation of human gastric epithelium cells. Toxicol Lett. 313:150–158. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tong SW, Yang YX, Hu HD, An X, Ye F, Hu P, Ren H, Li SL and Zhang DZ: Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem. 113:1671–1680. 2012.PubMed/NCBI
|
|
32
|
Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX and Xia JC: Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 54:598–607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, et al: ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Reports. 5:45–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pang RW and Poon RT: Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. Curr Cancer Drug Targets. 12:1081–1094. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nguyen LV, Vanner R, Dirks P and Eaves CJ: Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu Q, Pan QZ, Zhong AL, Hu H, Zhao JJ, Tang Y, Hu WM, Li M, Weng DS, Chen MY, et al: Annexin A3 upregulates the infiltrated neutrophil-lymphocyte ratio to remodel the immune microenvironment in hepatocellular carcinoma. Int Immunopharmacol. 89((Pt A)): 1071392020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang XR and Guo W: ASO Author Reflections: Annexin A3 as a potential biomarker for hepatocellular carcinoma. Ann Surg Oncol. 26 (Suppl 3):529–530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wozny W, Schroer K, Schwall GP, Poznanović S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, et al: Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3. Proteomics. 7:313–322. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Köllermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, et al: Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol. 54:1314–1323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeun M, Park S, Kim Y, Choi J, Song SH, Jeong IG, Kim CS and Lee KH: Self-normalized detection of ANXA3 from untreated urine of prostate cancer patients without digital rectal examination. Adv Healthc Mater. 6:17004492017. View Article : Google Scholar
|
|
41
|
Schostak M, Schwall GP, Poznanović S, Groebe K, Müller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, et al: Annexin A3 in urine: A highly specific noninvasive marker for prostate cancer early detection. J Urol. 181:343–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ, Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, et al: Tumor-suppressing effect of silencing of Annexin A3 expression in breast cancer. Clin Breast Cancer. 18:e713–e719. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li J, Zhou T, Liu L, Ju YC, Chen YT, Tan ZR and Wang J: The regulatory role of Annexin 3 in a nude mouse bearing a subcutaneous xenograft of MDA-MB-231 human breast carcinoma. Pathol Res Pract. 214:1719–1725. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zeng X, Wang S, Gui P, Wu H and Li Z: Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS. Mol Med Rep. 20:2583–2590. 2019.PubMed/NCBI
|
|
45
|
Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo CM, Man K, Ding J, et al: Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 69:826–839. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yan XD, Pan LY, Yuan Y, Lang JH and Mao N: Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res. 6:772–780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan X, Yin J, Yao H, Mao N, Yang Y and Pan L: Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 70:1616–1624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yin J, Yan X, Yao X, Zhang Y, Shan Y, Mao N, Yang Y and Pan L: Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med. 16:337–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li RL, Cao SS, Cui J, Wang L, Wu Y, et al: Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma. Asian Pac J Cancer Prev. 15:3191–3194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jin YF, Huang YT and Chen PF: ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin. Eur Rev Med Pharmacol Sci. 24:3741–3748. 2020.PubMed/NCBI
|
|
51
|
Thoenes L, Hoehn M, Kashirin R, Ogris M, Arnold GJ, Wagner E and Guenther M: In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy. J Proteomics. 73:1342–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Du R, Liu B, Zhou L, Wang D, He X, Xu X, Zhang L, Niu C and Liu S: Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer. Cell Death Dis. 9:1262018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu R, Yin J, Zhang Y and Zhang S: Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway. J Cell Biochem. 120:14585–14593. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zeng C, Ke Z, Song Y, Yao Y, Hu X, Zhang M, Li H and Yin J: Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance. Exp Mol Pathol. 95:23–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhou T, Li Y, Yang L, Liu L, Ju Y and Li C: Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells. Oncol Rep. 37:388–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou T, Li Y, Yang L, Tang T, Zhang L and Shi J: Annexin A3 as a prognostic biomarker for breast cancer: A retrospective study. BioMed Res Int. 2017:26036852017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhou T, Liu S, Yang L, Ju Y and Li C: The expression of ANXA3 and its relationship with the occurrence and development of breast cancer. J BUON. 23:713–719. 2018.PubMed/NCBI
|
|
58
|
Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, Chen YH, Yi H, Yao HX, et al: Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 217:54–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu Q, Wang S, Pei G, Yang Y, Min X, Huang Y and Liu J: Impact analysis of miR-1253 on lung cancer progression through targeted regulation of ANXA3. Cancer Manag Res. 13:1767–1776. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jung EJ, Moon HG, Park ST, Cho BI, Lee SM, Jeong CY, Ju YT, Jeong SH, Lee YJ, Choi SK, et al: Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. Proteomics Clin Appl. 4:528–537. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tan Y, Meng HP, Wu Q, Wang FQ and Wu HR: Proteomic study of gallbladder cancer, with special reference on the expression and significance of annexin A3. Zhonghua Bing Li Xue Za Zhi. 39:382–386. 2010.(In Chinese). PubMed/NCBI
|
|
62
|
Wang JW, Peng SY, Li JT, Wang Y, Zhang ZP, Cheng Y, Cheng DQ, Weng WH, Wu XS, Fei XZ, et al: Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 281:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yip KT, Das PK, Suria D, Lim CR, Ng GH and Liew CC: A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res. 29:1282010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Marshall KW, Mohr S, Khettabi FE, Nossova N, Chao S, Bao W, Ma J, Li XJ and Liew CC: A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 126:1177–1186. 2010.PubMed/NCBI
|
|
65
|
Madoz-Gúrpide J, López-Serra P, Martínez-Torrecuadrada JL, Sánchez L, Lombardía L and Casal JI: Proteomics-based validation of genomic data: Applications in colorectal cancer diagnosis. Mol Cell Proteomics. 5:1471–1483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xie YQ, Fu D, He ZH and Tan QD: Prognostic value of Annexin A3 in human colorectal cancer and its correlation with hypoxia-inducible factor-1α. Oncol Lett. 6:1631–1635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, Tajiri T, Kudo M, Ishiwata T and Naito Z: Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol. 78:123–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T and Chayama K: Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer. 40:1904–1912. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wan X, Guo D, Zhu Q and Qu R: microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3. Am J Physiol Gastrointest Liver Physiol. 319:G309–G322. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pompura SL and Dominguez-Villar M: The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol. 103:1065–1076. 2018. View Article : Google Scholar
|
|
71
|
Meng H, Zhang Y, An ST and Chen Y: Annexin A3 gene silencing promotes myocardial cell repair through activation of the PI3K/Akt signaling pathway in rats with acute myocardial infarction. J Cell Physiol. 234:10535–10546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jacobs MD and Harrison SC: Structure of an IkappaBalpha/NF-kappaB complex. Cell. 95:749–758. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 114:569–581. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao L, Meng Z, Wu X, Xu M and Xu K: Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Cancer Sci. 110:1609–1620. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang Y, Wang C, Yang Q and Cheng YL: ANXA3 silencing ameliorates intracranial aneurysm via inhibition of the JNK signaling pathway. Mol Ther Nucleic Acids. 17:540–550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Liu YF, Liu QQ, Zhang YH and Qiu JH: Annexin A3 knockdown suppresses lung adenocarcinoma. Anal Cell Pathol (Amst). 2016:41314032016.PubMed/NCBI
|
|
77
|
Xu B, Zhang X, Gao Y, Song J and Shi B: Microglial Annexin A3 promoted the development of melanoma via activation of hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway. J Clin Lab Anal. 35:e236222021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, et al: Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells. Stem Cells. 33:354–366. 2015. View Article : Google Scholar : PubMed/NCBI
|
